Trimetazidine protects umbilical cord mesenchymal stem cells against hypoxia and serum deprivation induced apoptosis by activation of Akt

Cellular Physiology and Biochemistry

Volumn 34, Issue 6, 2014, Pages 2245-2255

  Gong, Xuhe ^a   Fan, Guangpu ^a   Wang, Wei ^a   Wang, Guogan ^a  

^a FUWAI HOSPITAL   (China)

Author keywords

Apoptosis; Hypoxia and serum deprivation; Signaling pathway; Trimetazidine; Umbilical cord MSCs

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; HOE 33342; LIPOCORTIN 5; PROTEIN BCL 2; PROTEIN KINASE B; TRIMETAZIDINE; CULTURE MEDIUM;

APOPTOSIS; ARTICLE; ASSAY; HUMAN; HUMAN CELL; HYPOXEMIA; HYPOXIA; MESENCHYMAL STEM CELL; PRIORITY JOURNAL; PROTEIN MICROARRAY; SERUM; STAINING; SUPERNATANT; UMBILICAL CORD; WESTERN BLOTTING; BIOSYNTHESIS; CELL HYPOXIA; CULTURE MEDIUM; DRUG EFFECTS; GENE EXPRESSION REGULATION; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMA CELL; MYOCARDIAL INFARCTION; PATHOLOGY; PROTO ONCOGENE;

ANIMALIA;

APOPTOSIS; CELL HYPOXIA; CULTURE MEDIA, SERUM-FREE; GENE EXPRESSION REGULATION, DEVELOPMENTAL; GENES, BCL-2; HUMANS; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; MYOCARDIAL INFARCTION; PROTO-ONCOGENE PROTEINS C-AKT; TRIMETAZIDINE; UMBILICAL CORD;

EID: 84920934809     PISSN: 10158987     EISSN: 14219778     Source Type: Journal    
DOI: 10.1159/000369667     Document Type: Article

References (44)

1. Moran AE, Forouzanfar MH, Roth GA, Mensah GA, Ezzati M, Flaxman A, Murray CJ, Naghavi M: The global burden of ischemic heart disease in 1990 and 2010: The global burden of disease 2010 study. Circulation 2014;129:1493-1501
2. Schmidt MR, Pryds K, Botker HE: Novel adjunctive treatments of myocardial infarction. World J Cardiol 2014;6:434-443
3. Przybyt E, Harmsen MC: Mesenchymal stem cells: Promising for myocardial regeneration?. Curr Stem Cell Res Ther 2013;8:270-277
4. Vassalli G, Moccetti T: Cardiac repair with allogeneic mesenchymal stem cells after myocardial infarction. Swiss Med Wkly 2011;141:w13209
5. Wollert KC, Meyer GP, Lotz J, Ringes-Lichtenberg S, Lippolt P, Breidenbach C, Fichtner S, Korte T, Hornig B, Messinger D, Arseniev L, Hertenstein B, Ganser A, Drexler H: Intracoronary autologous bone-marrow cell transfer after myocardial infarction: The boost randomised controlled clinical trial. Lancet 2004;364:141-148
6. Lunde K, Solheim S, Aakhus S, Arnesen H, Abdelnoor M, Egeland T, Endresen K, Ilebekk A, Mangschau A, Fjeld JG, Smith HJ, Taraldsrud E, Grogaard HK, Bjornerheim R, Brekke M, Muller C, Hopp E, Ragnarsson A, Brinchmann JE, Forfang K: Intracoronary injection of mononuclear bone marrow cells in acute myocardial infarction. N Engl J Med 2006;355:1199-1209
7. Zhang M, Methot D, Poppa V, Fujio Y, Walsh K, Murry CE: Cardiomyocyte grafting for cardiac repair: Graft cell death and anti-death strategies. J Mol Cell Cardiol 2001;33:907-921
8. Stadnik M, Handzlik-Orlik G, Sarnecki K, Krysiak R, Okopien B: [clinical aspects of the use of trimetazidine in the prevention and treatment of myocardial diseases]. Przegl Lek 2013;70:730-734
9. Wu Q, Qi B, Liu Y, Cheng B, Liu L, Li Y, Wang Q: Mechanisms underlying protective effects of trimetazidine on endothelial progenitor cells biological functions against h2o2-induced injury: Involvement of antioxidation and akt/enos signaling pathways. Eur J Pharmacol 2013;707:87-94
10. Xu H, Zhu G, Tian Y: Protective effects of trimetazidine on bone marrow mesenchymal stem cells viability in an ex vivo model of hypoxia and in vivo model of locally myocardial ischemia. J Huazhong Univ Sci Technolog Med Sci 2012;32:36-41
11. Fu YS, Cheng YC, Lin MY, Cheng H, Chu PM, Chou SC, Shih YH, Ko MH, Sung MS: Conversion of human umbilical cord mesenchymal stem cells in wharton's jelly to dopaminergic neurons in vitro: Potential therapeutic application for parkinsonism. Stem Cells 2006;24:115-124
12. Hsieh JY, Wang HW, Chang SJ, Liao KH, Lee IH, Lin WS, Wu CH, Lin WY, Cheng SM: Mesenchymal stem cells from human umbilical cord express preferentially secreted factors related to neuroprotection, neurogenesis, and angiogenesis. PloS One 2013;8:e72604
13. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, Deans R, Keating A, Prockop D, Horwitz E: Minimal criteria for defining multipotent mesenchymal stromal cells. The international society for cellular therapy position statement. Cytotherapy 2006;8:315-317
14. Wisel S, Khan M, Kuppusamy ML, Mohan IK, Chacko SM, Rivera BK, Sun BC, Hideg K, Kuppusamy P: Pharmacological preconditioning of mesenchymal stem cells with trimetazidine (1-[2, 3, 4-Trimethoxybenzyl]piperazine) protects hypoxic cells against oxidative stress and enhances recovery of myocardial function in infarcted heart through bcl-2 expression. J pharmacol Exp Ther 2009;329:543-550
15. Nascimento DS, Mosqueira D, Sousa LM, Teixeira M, Filipe M, Resende TP, Araujo AF, Valente M, Almeida J, Martins JP, Santos JM, Barcia RN, Cruz P, Cruz H, Pinto-do OP: Human umbilical cord tissue-derived mesenchymal stromal cells attenuate remodeling following myocardial infarction by pro-Angiogenic, anti-Apoptotic and endogenous cell activation mechanisms. Stem cell Res Ther 2014;5:5
16. Miyahara Y, Nagaya N, Kataoka M, Yanagawa B, Tanaka K, Hao H, Ishino K, Ishida H, Shimizu T, Kangawa K, Sano S, Okano T, Kitamura S, Mori H: Monolayered mesenchymal stem cells repair scarred myocardium after myocardial infarction. Nat Med 2006;12:459-465
17. van Der Bogt KE, Sheikh AY, Schrepfer S, Hoyt G, Cao F, Ransohoff KJ, Swijnenburg RJ, Pearl J, Lee A, Fischbein M, Contag CH, Robbins RC, Wu JC: Comparison of different adult stem cell types for treatment of myocardial ischemia. Circulation 2008;118:S121-129
18. Imanishi Y, Saito A, Komoda H, Kitagawa-Sakakida S, Miyagawa S, Kondoh H, Ichikawa H, Sawa Y: Allogenic mesenchymal stem cell transplantation has a therapeutic effect in acute myocardial infarction in rats. J Mol Cell Cardiol 2008;44:662-671
19. Mazo M, Planat-Benard V, Abizanda G, Pelacho B, Leobon B, Gavira JJ, Penuelas I, Cemborain A, Penicaud L, Laharrague P, Joffre C, Boisson M, Ecay M, Collantes M, Barba J, Casteilla L, Prosper F: Transplantation of adipose derived stromal cells is associated with functional improvement in a rat model of chronic myocardial infarction. Eur J Heart Fail 2008;10:454-462
20. Tang YL, Tang Y, Zhang YC, Qian K, Shen L, Phillips MI: Improved graft mesenchymal stem cell survival in ischemic heart with a hypoxia-regulated heme oxygenase-1 vector. J Am Coll of Cardiol 2005;46:1339-1350
21. Song L, Yang YJ, Dong QT, Qian HY, Gao RL, Qiao SB, Shen R, He ZX, Lu MJ, Zhao SH, Geng YJ, Gersh BJ: Atorvastatin enhance efficacy of mesenchymal stem cells treatment for swine myocardial infarction via activation of nitric oxide synthase. PloS One 2013;8:e65702
22. Xu R, Chen J, Cong X, Hu S, Chen X: Lovastatin protects mesenchymal stem cells against hypoxia-And serum deprivation-induced apoptosis by activation of pi3k/akt and erk1/2. J Cell Biochem 2008;103:256-269
23. Li N, Yang YJ, Cui HH, Zhang Q, Jin C, Qian HY, Dong QT, Zhang H: Tongxinluo decreases apoptosis of mesenchymal stem cells concentration-dependently under hypoxia and serum deprivation conditions through the ampk/enos pathway. J Cardiovasc Pharmacol 2014;63:265-273
24. Kim JS, Kim CH, Chun KJ, Kim JH, Park YH, Kim J, Choi JH, Lee SH, Kim EJ, Yu DG, Ahn EY, Jeong MH: Effects of trimetazidine in patients with acute myocardial infarction: Data from the korean acute myocardial infarction registry. Clin Res Cardiol 2013;102:915-922
25. Tsioufis K, Andrikopoulos G, Manolis A: Trimetazidine and cardioprotection: Facts and perspectives. Angiology DOI: 10.1177/0003319714530040
26. Ruixing Y, Wenwu L, Al-Ghazali R: Trimetazidine inhibits cardiomyocyte apoptosis in a rabbit model of ischemia-reperfusion. Transl Res 2007;149:152-160
27. Dedkova EN, Seidlmayer LK, Blatter LA: Mitochondria-mediated cardioprotection by trimetazidine in rabbit heart failure. J Mol Cell Cardiol 2013;59:41-54
28. Grayson WL, Zhao F, Bunnell B, Ma T: Hypoxia enhances proliferation and tissue formation of human mesenchymal stem cells. Biochem Biophys Res Commun 2007;358:948-953
29. Potier E, Ferreira E, Andriamanalijaona R, Pujol JP, Oudina K, Logeart-Avramoglou D, Petite H: Hypoxia affects mesenchymal stromal cell osteogenic differentiation and angiogenic factor expression. Bone 2007;40:1078-1087
30. Ohnishi S, Yasuda T, Kitamura S, Nagaya N: Effect of hypoxia on gene expression of bone marrow-derived mesenchymal stem cells and mononuclear cells. Stem Cells 2007;25:1166-1177
31. Rochefort GY, Delorme B, Lopez A, Herault O, Bonnet P, Charbord P, Eder V, Domenech J: Multipotential mesenchymal stem cells are mobilized into peripheral blood by hypoxia. Stem Cells 2006;24:2202-2208
32. Zhu W, Chen J, Cong X, Hu S, Chen X: Hypoxia and serum deprivation-induced apoptosis in mesenchymal stem cells. Stem Cells 2006;24:416-425
33. Potier E, Ferreira E, Meunier A, Sedel L, Logeart-Avramoglou D, Petite H: Prolonged hypoxia concomitant with serum deprivation induces massive human mesenchymal stem cell death. Tissue Eng 2007;13:1325-1331
34. Das R, Jahr H, van Osch GJ, Farrell E: The role of hypoxia in bone marrow-derived mesenchymal stem cells: Considerations for regenerative medicine approaches. Tissue Eng Part B Rev 2010;16:159-168
35. Herrmann JL, Markel TA, Abarbanell AM, Weil BR, Wang M, Wang Y, Tan J, Meldrum DR: Proinflammatory stem cell signaling in cardiac ischemia. Antioxid Redox Signal 2009;11:1883-1896
36. Sussman MA, Volkers M, Fischer K, Bailey B, Cottage CT, Din S, Gude N, Avitabile D, Alvarez R, Sundararaman B, Quijada P, Mason M, Konstandin MH, Malhowski A, Cheng Z, Khan M, McGregor M: Myocardial akt: The omnipresent nexus. Physiol Rev 2011;91:1023-1070
37. Mangi AA, Noiseux N, Kong D, He H, Rezvani M, Ingwall JS, Dzau VJ: Mesenchymal stem cells modified with akt prevent remodeling and restore performance of infarcted hearts. Nat Med 2003;9:1195-1201
38. Zhang H, Li F, Pan Z, Wu Z, Wang Y, Cui Y: Activation of pi3k/akt pathway limits jnk-mediated apoptosis during ev71 infection. Virus Res 2014;192:74-84
39. Fujio Y, Nguyen T, Wencker D, Kitsis RN, Walsh K: Akt promotes survival of cardiomyocytes in vitro and protects against ischemia-reperfusion injury in mouse heart. Circulation 2000;101:660-667
40. Liu CH, Hwang SM: Cytokine interactions in mesenchymal stem cells from cord blood. Cytokine 2005;32:270-279
41. Boomsma RA, Geenen DL: Mesenchymal stem cells secrete multiple cytokines that promote angiogenesis and have contrasting effects on chemotaxis and apoptosis. PloS One 2012;7:e35685
42. Jin H, Sanberg PR, Henning RJ: Human umbilical cord blood mononuclear cell-conditioned media inhibits hypoxic-induced apoptosis in human coronary artery endothelial cells and cardiac myocytes by activation of the survival protein akt. Cell Transplant 2013;22:1637-1650
43. Du L, Yu Y, Ma H, Lu X, Ma L, Jin Y, Zhang H: Hypoxia enhances protective effect of placental-derived mesenchymal stem cells on Damaged intestinal epithelial cells by promoting secretion of insulin-like growth factor-1. Int J Mol Sci 2014;15:1983-2002.
44. Risbud MV, Fertala J, Vresilovic EJ, Albert TJ, Shapiro IM: Nucleus pulposus cells upregulate pi3k/akt and mek/erk signaling pathways under hypoxic conditions and resist apoptosis induced by serum withdrawal. Spine 2005;30:882-889